Mode
Text Size
Log in / Sign up

Deep Vein Thrombosis

Part of Embolism and Thrombosis

7 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Deep Vein Thrombosis

41 trials tracked for Deep Vein Thrombosis: 15 in phase 3 or 4 and 6 with published results. The most-cited published study has 576 citations.

41Trials tracked
15Phase 3 & 4
0Recruiting
6With published results
Phase distribution
Phase 4 7 Phase 3 8 Phase 2 7 Phase 1 2 Other / NA 17
  1. Phase 3 Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism Completed · 576 cited
  2. Phase 3 Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis Completed · 86 cited
  3. Phase 3 Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy Completed · 54 cited
  4. Phase 4 Rivaroxaban With Diosmin in Long-term Treatment of Deep Vein Thrombosis Completed · 36 cited
  5. Phase 4 Treatment of Chronic Deep Vein Thrombosis (DVT) and Post-Thrombotic Syndrome (PTS) With the EkoSonic® Endovascular System Completed · 36 cited
  6. Phase 4 Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism Completed · 28 cited
Show 35 more trials
  1. Phase 4 Venous Thromboembolic Prophylaxis After Trauma: Three Times a Day Unfractionated Heparin Versus Twice a Day Enoxaparin Completed
  2. Phase 4 Treatment of Upper Extremity Deep-Vein Thrombosis Completed
  3. Phase 4 Innohep® in Elderly Patients With Impaired Renal Function Treated for Acute Deep Vein Thrombosis Completed
  4. Phase 4 Comparison of Warfarin Dosing Using Decision Model Versus Pharmacogenetic Algorithm Completed
  5. Phase 3 AStudy To Evaluate Safety And Eficacy Of Apixaban In Japanese Acute Deep Vein Thrombosis (DVT) And Pulmonary Embolism (PE) Patients Completed
  6. Phase 3 A Safety and Efficacy Study of BCD-080 Compared to Clexan for Deep Vein Thrombosis Prophylaxis at Orthopedic Surgeries Completed
  7. Phase 3 Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3) Completed
  8. Phase 3 Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery Completed
  9. Phase 3 Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery Completed
  10. Phase 2 Weight-Based Enoxaparin Dosing and Real-Time Dose Adjustment in Orthopaedic Trauma Completed
  11. Phase 2 A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis Completed
  12. Phase 2 A Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty Completed
  13. Phase 2 A Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty Completed
  14. Phase 2 Deep Vein Thrombosis Treatment With the Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients Using a Strong CYP 3A4 Inducer Completed
  15. Phase 2 Clinical Trial to Evaluate the Accuracy of [99mTc] ThromboView in the Detection of Deep Vein Thrombosis Completed
  16. Phase 2 Odiparcil For The Prevention Of Venous Thromboembolism Completed
  17. Phase 1 Phase 1 Pediatric Pharmacokinetics/Pharmacodynamics (PK/PD) Study Completed
  18. Phase 1 Safety Study of the Angel™ Catheter in Subjects With Risk of Pulmonary Embolism Completed
  19. N/A Incidence of Venous Thromboembolism in Children Undergoing Elective Neurosurgical Procedures Completed
  20. N/A Study to Develop a Reliable Nomogram That Incorporates Clinical and Genetic Information Completed
  21. N/A Clinical Predictors for Venous Thromboembolism in Patients With a History of Thrombosis (PREDICTORS) Completed
  22. N/A Blood Flow Stimulation in the Lower Limbs by Application of Different External Devices Completed
  23. N/A Determining the Validity of ThinkSono Guidance for Ultrasound Image Acquisition and Remote Detection Completed
  24. N/A The Risk of Venous Thromboembolism in Systemic Inflammatory Disorders: a United Kingdom (UK) Matched Cohort Study Completed
  25. N/A The Angel® Catheter Pivotal Clinical Trial Completed
  26. N/A Once Daily Enoxaparin for Outpatient Treatment of Acute DVT and/or Pulmonary Embolism Completed
  27. N/A The SENTRY Clinical Study Completed
  28. N/A OsciPulse Device for the Prevention of VTE Completed
  29. N/A Randomized Trial of Interventions to Improve Warfarin Adherence Completed
  30. N/A A Preliminary Clinical Usability Study for the Recovery Force DVT II Cuff Completed
  31. N/A The Incidence of Venous Thromboembolism in Atopic Dermatitis Completed
  32. N/A Physical Activity in Children at Risk of Post-thrombotic Sequelae (PACT) Completed
  33. N/A Pilot Study for VeinoPlus to Improve Symptoms of Postthrombotic Syndrome (PTS) Completed
  34. N/A Venous Stent for the Iliofemoral Vein Investigational Clinical Trial Using the DUO Venous Stent System Completed
  35. N/A Comparison of Different Intermittent Pneumatic Compression Devices for Deep Vein Thrombosis Completed

Showing the 41 most-cited and recently-updated of 41 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Embolism and Thrombosis

Related studies from across the Embolism and Thrombosis family.

Intravitreal ziv-aflibercept reduces central macular thickness and improves visual acuity in DME and RVO
Ophthalmology Meta-analysis
Intravitreal ziv-aflibercept reduces central macular thickness and improves visual acuity in DME and RVO Trial shows ziv-aflibercept improves vision in macular edema cases
This systematic review and meta-analysis of 5 RCTs and 8 observational studies found that intravitreal ziv-aflibercept significantly reduced…
A new eye treatment called ziv-aflibercept may help reduce swelling and improve vision for patients with specific types of macular edema.
Systematic review of Dendrobium phenanthrene bioactivity across multiple disease models
Drug Pipeline Sys. Review
Systematic review of Dendrobium phenanthrene bioactivity across multiple disease models Scientists found many plant chemicals that fight cancer and help diabetes in lab tests
This systematic review evaluates the bioactivity of 158 phenanthrene metabolites isolated from 53 Dendrobium taxa. The authors note that 64 …
A review of plant chemicals from Dendrobium plants shows strong activity against cancer and diabetes in lab studies. Most results come from …
FDA Approves Pavblu (aflibercept) for Neovascular AMD, RVO, DME, and DR
Ophthalmology FDA Approval
FDA Approves Pavblu (aflibercept) for Neovascular AMD, RVO, DME, and DR FDA approves Pavblu to treat several eye conditions that cause vision loss.
The FDA approved Pavblu (aflibercept) for neovascular AMD, macular edema following RVO, DME, and DR. It is a VEGF inhibitor administered by …
The FDA approved Pavblu (aflibercept) for wet age-related macular degeneration, macular edema, diabetic macular edema, and diabetic retinopa…
Systematic review and meta-analysis finds high prevalence of ocular manifestations in leukemia patients
Hematology Meta-analysis
Systematic review and meta-analysis finds high prevalence of ocular manifestations in leukemia patients Leukemia patients face eye risks that doctors must spot early now
This systematic review and meta-analysis of 1016 patients with leukemia found a 42% prevalence of overall ocular manifestations.
New data shows almost half of leukemia patients have eye issues, so regular eye checks are essential for better care
COVID-19 pandemic linked to no significant change in retinal vascular occlusion incidence at a Swiss eye hospital
Ophthalmology Cohort
COVID-19 pandemic linked to no significant change in retinal vascular occlusion incidence at a Swiss eye hospital COVID-19 Did Not Raise Eye Stroke Risk, Study Finds
This retrospective cohort study compared retinal vascular occlusion diagnoses in 2019 versus 2020 at a Swiss eye hospital.
New eye data shows COVID’s first year did not raise the risk of retinal vein or artery blockages.
Retrospective study links systemic BP control to better visual outcomes with conbercept for RVO-related macular edema
Dermatology Cohort
Retrospective study links systemic BP control to better visual outcomes with conbercept for RVO-related macular edema Your Blood Pressure May Decide How Well Eye Injections Work
A retrospective cohort study of 76 hypertensive patients with macular edema secondary to retinal vein occlusion found that those with contro…
If you need eye injections for fluid swelling behind the retina, keeping your blood pressure in check could decide how much vision you get b…
Meta-analysis finds increased bleeding with antithrombotic therapy during breast biopsy, but clinically relevant events are rare
Oncology Meta-analysis
Meta-analysis finds increased bleeding with antithrombotic therapy during breast biopsy, but clinically relevant events are rare Continuing blood thinners during breast biopsy increases minor bleeding but rarely serious problems
A systematic review and meta-analysis of 8 studies including 11,524 patients undergoing image-guided breast biopsy found that continuing ant…
Continuing blood thinners during a breast biopsy slightly increases minor bleeding but rarely causes serious problems like heart attacks or …

Questions about Deep Vein Thrombosis

Does Xarelto help prevent stroke in patients with nonvalvular atrial fibrillation and Deep Vein Thrombosis?

Yes, Xarelto (rivaroxaban) is FDA-approved to reduce stroke risk in nonvalvular atrial fibrillation and to treat deep vein thrombosis, making it effective for patients with both conditions.

Full answer →
Can the FDA-approved drug Xarelto be used to treat Deep Vein Thrombosis?

Yes, Xarelto (rivaroxaban) is FDA-approved for treating deep vein thrombosis (DVT) and reducing the risk of recurrent DVT.

Full answer →
Can education help lower my risk of Deep Vein Thrombosis after orthopedic surgery?

Yes, education can help lower your risk of DVT after orthopedic surgery. A meta-analysis found that patients who received education had about half the risk of developing DVT compared to those who did not.

Full answer →